Wednesday, July 8, 2026

Patent intelligence · US

US 12077543

P2X3 and/or P2X2/3 compounds and methods

granted A61PA61P11/00A61P11/06A61P11/08
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 136
Patent details — US 12077543
Jurisdiction
US
Status
granted
Grant date
Sep 3, 2024
Expiration
Aug 29, 2044
Claims
2
CPC classes
A61P, A61P11/00, A61P11/06, A61P11/08
View on Google Patents ↗

Quick answer

US 12077543 (P2X3 and/or P2X2/3 compounds and methods) is held by Asana BioSciences, LLC. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
2
CPC classes
A61P, A61P11/00, A61P11/06, A61P11/08, A61P25/00, A61P25/04

More from Asana BioSciences, LLC

Related pharmaceutical patents in our USPTO index.

  1. US 12427199

    Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

    RS ARASTIRMA EGITIM DANISMANLIK ILAC SANAYI TICARET ANONIM SIRKETI · Expires Sep 25, 2045

    granted
  2. US 12409213

    Live attenuated oral vaccine against shigellosis and typhoid fever

    Sanaria Inc. · Expires Sep 4, 2045

    granted
  3. US 12246059

    Stable hybrid FC fusion G-CSF formulation

    ILKOGEN ILAÇ SANAYI VE TICARET A.S. · Expires Mar 6, 2045

    granted
  4. US 12171822

    Infectious plasmodium sporozoites grown in vitro

    Sanaria Inc. · Expires Dec 19, 2044

    granted
  5. US 12156870

    Antibody drug conjugates comprising sting agonists

    Mersana Therapeutics, Inc. · Expires Nov 28, 2044

    granted
  6. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Sanabio, LLC · Expires Oct 24, 2044

    granted
  7. US 11987628

    Methods and compositions for modulating CAR-T activity

    Sana Biotechnology, Inc. · Expires May 16, 2044

    granted

Frequently asked questions

What is US patent 12077543?

US 12077543 (P2X3 and/or P2X2/3 compounds and methods) is held by Asana BioSciences, LLC. Status: granted. Granted Sep 3, 2024. Expires Aug 29, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12077543?

Asana BioSciences, LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 136 pharmaceutical patents for this assignee.

When does US 12077543 expire?

Our index shows an expiration date of Aug 29, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.